As the United Arab Emirates (UAE) continues to position itself as a leader in innovation, significant developments have emerged in its research and development (R&D) landscape. On April 12, 2026, Sheikh Khaled bin Mohamed bin Zayed Al Nahyan arrived in Beijing, China, marking a pivotal moment for UAE’s international collaborations and advancements in technology.
In recent years, the UAE’s 3D ultrasound market has transitioned from a high-end niche to a procedural standard, driven by clinical demand for volumetric quantification in prenatal cardiology and image-guided interventions. This shift underscores the UAE’s role as a regional reference and training hub for advanced ultrasound applications.
Concurrently, the UAE government has introduced an R&D tax credit regime, established under Cabinet Decision No. 215 of 2025, which has now been operationalized through Ministerial Decision No. 24 of 2026. This initiative aims to stimulate innovation and investment in the healthcare sector.
The R&D tax credit features a tiered structure with three levels: 15% for qualifying expenditures of up to 1 million AED, 35% for expenditures between 1 million and 2 million AED, and 50% for amounts exceeding 5 million AED. This structure is designed to incentivize companies to invest in research and development, thereby enhancing the UAE’s competitive edge.
Furthermore, the UAE’s R&D tax credit has a headline rate of 50% on qualifying expenditure, making it one of the most attractive regimes in the region. However, compliance with transfer pricing (TP) regulations is a prerequisite for credit qualification, emphasizing the importance of transparency and accountability in financial practices.
The implications of these developments are significant. The acceleration of the installed base refresh cycle, driven by software-driven obsolescence, indicates a growing demand for updated technology in the healthcare sector. As the UAE continues to innovate, it is likely to attract more international partnerships and investments.
Moreover, the dual-threshold design of the R&D tax credit has direct TP implications, as the headcount requirement cannot be satisfied through intra-group secondments recharged from other tax group members. This stipulation aims to ensure that R&D activities are genuinely conducted within the UAE, further solidifying its position as a hub for technological advancement.
As of now, the UAE stands at a crossroads, with its R&D landscape evolving rapidly. The combination of government support, market demand, and international collaboration is poised to drive further advancements in healthcare technology.
These developments matter not only for the UAE’s economy but also for the global healthcare community, as they may lead to improved medical technologies and practices. The ongoing commitment to R&D will likely enhance the quality of care available to patients both locally and internationally.